Medical Biotechnology

Pipette adding blue fluid test tube close up | © Stockphoto/Chet Chaimangkhalayon

Medical Biotechnology

Where Science, Innovation and Quality Meet

Germany is the world’s leading medical biotech nation behind the US. The industry’s strength comes from the presence of long-established and start-up companies alike. Industry, government, and the research sector are pulling in one direction to build on the thriving sector’s already strong market foundations. With the largest amount of biotech companies in Europe, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub.

Latest Publication

Fact Sheet: Biotechnology Clusters in Germany | © GTAI Biotechnology Clusters in Germany

Germany features one of the best environments for biotechnology companies worldwide. Along the entire value chain Germany's biotechnology landscape is known for its outstanding capabilities, resources, and infrastructure. More

Facts & Figures

Key figures of the biotech sector in Germany (2016)

Number of dedicated biotechnology companies615
Number of other biotechnology-active companies137
Number of employees in dedicated companies20,280
Number of employees in the other biotechnology-active companies22,000
Revenue of dedicated biotechnology companies EUR bn3.54
R&D expenditures of dedicated biotechnology companies EUR bn1.1

Revenue of dedicated biotechnology companies in EUR billion | © Biocom AG 2017

Innovation Infrastructure

Science and industry need to work together closely in order for innovations to be commercialized successfully. German bioclusters are proving to be important new technology impulse givers in this respect.

Germany’s Bioregions

The BioRegions are regional initiatives for the advancement of modern biotechnology in Germany. Over the past three decades, these biotechnology clusters have developed to become Europe’s leading R&D hubs. Each region facilitates collaboration between universities, R&D institutes and private sector companies. Around 30 BioRegions are active members of AK Bioregio, whose goal is to advance the German biotechnology sector by coordinating and promoting local activities. AK BioRegio advances the exchange between regional initiatives and relays its expertise to political decision makers.

Investors benefit from easy access to networks and funding for research projects. The BioRegions also include technology parks tailored to the specific needs of biotechnology companies. Commonly known as BioParks, these centers offer an ideal infrastructure - including lab space and clean rooms - as well as a range of services for both start-up and well established companies.

Growth drivers: Biopharmaceuticals Market

Big pharmaceutical and smaller biotechnology companies alike are focusing on drug discovery and development of medicines produced by biotechnological processes.

Small molecules are moving to the background in medicine development as the result of a major paradigm shift to biopharmaceuticals. This is reflected by the increasing sales of biopharmaceutical products worldwide.

According to a report by Boston Consulting Group and the Association of Research-Based Pharmaceutical Companies (vfa), sales of biopharmaceuticals in Germany increased to EUR 8.2 billion in 2015 (growth of 9.7 percent compared to 2014). Growth was seen in nearly all fields of application, particularly in drugs treating immunological (e.g. rheumatic) diseases and cancer.

The number of biopharmaceuticals in clinical development increased by four percent from 604 to 627 in 2015, reflecting continued high investment in the biopharmaceutical pipeline.

With 50 new drugs approved, the approval rate was the highest in more than 10 years and also included a record 15 biopharmaceuticals (30 percent of total). By the end of 2015 a total of 240 biopharmaceutical drugs were approved for the German market – more than ever before. Divided into pharmacological classes, 60 vaccines account for the majority of all products (25 percent), followed by the 43 monoclonal antibodies (26 percent increase over previous year).

Number of new drug approvals | © Federal Statistics Office 2015

Biopharmaceuticals Value Growth Rate in percent | © IMS Health, Boston Consulting Group 2016

Growth drivers: IVD & Molecular Diagnostics

In-vitro diagnostics (IVDs) are a crucial part of modern medicine: laboratory based tests performed on biological samples provide information that is key for the prevention, treatment and management of diseases. Today, around two third of all clinical diagnoses are made thanks to IVD´s. With more than EUR 2 bn in annual revenue, Germany represents the largest IVD market in Europe and second worldwide behind the USA.

Diagnostic industry revenue in EUR million | © EDMA 2016

Molecular diagnostics (Dx) has emerged as one of the largest and fastest growing sectors of the IVD industry. Molecular Dx already enjoys more than 10 percent share of the entire German diagnostics market and boasts a growth rate more than twice that of the entire IVD market as such.


Dr. Sandra M. Bütow Sandra Bütow | © GTAI/Illing & Vossbeck Fotografie

Contact Us

Dr. Sandra M. Bütow

‎+49 30 200 099 604

Logo WEBINAR 2016 Market Access and Regulatory Update for Medical Technologiy| © GTAI

Webinar Series 2017

Logo Webinar Germany Trade & Invest | © Fotolia - Maksim Kabakou

Webinar Series 2013 - 2017

Meet Us

ipad | © bloomua -


Sign up for our free Medical Biotechnology Information Service to receive occasional industry news and event updates.

Logo: Mittelstqand Global - HEALTH MADE IN GERMANY | © 2016 Bundesministerium für Wirtschaft und Technologie

The initiative HEALTH MADE IN GERMANY helps to bring the strengths of the German health care industry to countries around the globe.

Customer Service

Step by step to success - have a look at our comprehensive line of services and see how we will help your business grow in Germany.